These findings together have the intriguing therapeutic possibility of targeting FAK as a key signalling pathway downstream of RET to block tumour growth and metastatic potential not only in ER-positive breast cancers but also, potentially, in other breast cancer subtypes. Here, PTK2 is linked to breast carcinoma.